What 4 Analyst Ratings Have To Say About Elevance Health
Portfolio Pulse from Benzinga Insights
Elevance Health (NYSE:ELV) received four somewhat bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for ELV is $558.25, which is a 3.25% decrease from the previous target of $577.00. Analysts provide ratings based on financial statements, meetings, and insider information, and these ratings are updated quarterly.
November 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Elevance Health received four somewhat bullish ratings from analysts with an average price target of $558.25, indicating a slight decrease in optimism compared to the previous target of $577.00.
The somewhat bullish ratings and the slight decrease in the average price target suggest a neutral to mildly positive outlook for ELV in the short term. The lack of bearish or indifferent ratings indicates a general consensus of cautious optimism among analysts, which may not significantly move the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100